A.M. van Tubergen

Carbo, M., Kampman, A., Paap, D., Wink, F., Webers, C., Vonkeman, H., van Tubergen, A., Arends, S., & Spoorenberg, A. (2026). Almost half of the patients with axial spondyloarthritis reporting an acceptable symptom state have high disease activity; data from two standard-of-care cohorts. Seminars in Arthritis and Rheumatism, 77, Article 152903. https://doi.org/10.1016/j.semarthrit.2025.152903

Smits, M. L., Renet, E., Vonkeman, H. E., Webers, C., & van Tubergen, A. (2026). Predictive Value of Severe Symptoms for Residual Disease After Transitioning From High to Low Disease Activity in Axial Spondyloarthritis: A Longitudinal Study. Journal of Rheumatology, 53(4), 386-394. https://doi.org/10.3899/jrheum.2025-0421

Smits, M. L., Webers, C., & van Tubergen, A. (2026). Evidence-based follow-up in axial spondyloarthritis: how much is (not) enough? Current Opinion in Rheumatology. Advance online publication. https://doi.org/10.1097/BOR.0000000000001158

Hochstenbach, L. M. J., Verbeek, J. G. E., Brokken-Peters, M. B. J., van den Dungen, P., Knops, A. M., Spreeuwenberg, M. D., Vonkeman, H. E., & van Tubergen, A. (2026). Evaluation of a web-based self-monitoring application (MyRA) to empower people with rheumatoid arthritis in daily life. Rheumatology, 65(2), Article keaf565. https://doi.org/10.1093/rheumatology/keaf565

Ramiro, S., Proft, F., Sengupta, R., van Tubergen, A., Molto, A., Gensler, L. S., Kishimoto, M., Taieb, V., Kavanagh, S., Evans, S., & Navarro-Compan, V. (2026). Impact of symptom duration on the short- and long-term efficacy of bimekizumab in axial spondyloarthritis: results up to 2 years. Arthritis Research & Therapy, 28(1), Article 40. https://doi.org/10.1186/s13075-026-03729-6

Iken, A. R., Gademan, M. G. J., Vliet Vlieland, T. P. M., Nutma, A., van Gaalen, F. A., van Tubergen, A. M., Poolman, R. W., van Bodegom-Vos, L., & L-EXTRA and L-EXSPA Implementation Study Group (2026). Barriers and facilitators to implement longstanding exercise therapy for people with rheumatoid arthritis or axial spondyloarthritis. Rheumatology advances in practice, 10(1), Article rkag013. https://doi.org/10.1093/rap/rkag013

Nezam El-Din, R., van Tubergen, A., Vonkeman, H. E., & Webers, C. (2025). Which ASDAS cut-off corresponds best to treatment intensification in patients with axial spondyloarthritis in daily practice? A prospective study from a clinical registry. Rheumatology International, 45(11), Article 256. https://doi.org/10.1007/s00296-025-06011-1

Roumen, C., Hochstenbach, L. M., van den Dungen, P., Knops, A. M., Brokken-Peters, M. B., Spreeuwenberg, M. D., Vonkeman, H. E., & van Tubergen, A. (2025). Development of an application for self-monitoring to empower patients with rheumatoid arthritis (MyRA). Journal of Rheumatology, 52(7), 647-654. https://doi.org/10.3899/jrheum.2024-1071

Smits, M. L., Webers, C., Vonkeman, H. E., & van Tubergen, A. (2025). Exploring difficult-to-manage axial spondyloarthritis: results from a Dutch clinical practice registry. Rheumatology, 64(6), 3816-3825. https://doi.org/10.1093/rheumatology/keaf120

Smits, M. L., Hermans, K., Boonen, A., Vonkeman, H. E., Webers, C., & van Tubergen, A. (2025). Experiences with patient-initiated follow-up supported by asynchronous telemedicine in spondyloarthritis: a mixed methods study. Rheumatology, 64(5), 2631-2639. https://doi.org/10.1093/rheumatology/keae650